Tacforius 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0013/G 
This was an application for a group of variations. 
10/01/2023 
SmPC and PL 
Update of sections 4.4 and 4.8 of the SmPC in order to add 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
a warning on the adverse reaction Thrombotic 
microangiopathy (TMA) following assessment of the same 
changes adopted for the parent product 
(EMEA/H/C/2241/G). The package leaflet is updated 
accordingly. Update of sections 4.5 and 4.8 of the SmPC in 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
order to add the drug-drug interaction between tacrolimus 
and caspofungin following assessment of the same changes 
adopted for the parent product. The package leaflet is 
updated accordingly. Update of section 5.2 of the SmPC in 
order to add that tacrolimus is metabolized by the 
cytochrome P450-3A5 (CYP3A5) following assessment of 
the same changes adopted for the parent product. The 
package leaflet is updated accordingly. 
In addition, the MAH took the opportunity to implement 
minor editorial changes.  
IA/0012 
B.III.1.a.2 - Submission of a new/updated or 
06/09/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
R/0010 
Renewal of the marketing authorisation. 
23/06/2022 
05/08/2022 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Tacforius in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IB/0011/G 
This was an application for a group of variations. 
08/06/2022 
05/08/2022 
SmPC, Annex 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
II, Labelling 
and PL 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0009 
A.7 - Administrative change - Deletion of 
25/10/2021 
n/a 
manufacturing sites 
N/0007 
Minor change in labelling or package leaflet not 
09/07/2021 
05/08/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0008 
B.III.1.a.2 - Submission of a new/updated or 
17/06/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0006 
B.II.b.3.z - Change in the manufacturing process of 
08/10/2020 
n/a 
the finished or intermediate product - Other variation 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0005 
B.III.1.a.1 - Submission of a new/updated or 
18/09/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0004/G 
This was an application for a group of variations. 
16/04/2020 
26/03/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0003/G 
This was an application for a group of variations. 
02/10/2019 
17/02/2020 
SmPC, Annex 
II, Labelling 
and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment done under A 45/46 - Other variation 
IAIN/0002 
C.I.z - Changes (Safety/Efficacy) of Human and 
28/02/2019 
17/02/2020 
SmPC 
Veterinary Medicinal Products - Other variation 
IA/0001 
B.II.d.2.a - Change in test procedure for the finished 
06/02/2019 
n/a 
product - Minor changes to an approved test 
procedure 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
 
